Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $635.9 million.

  • Ptc Therapeutics' Non-Current Assets rose 1341.41% to $635.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 3067.49%. This contributed to the annual value of $339.5 million for FY2024, which is 4985.84% down from last year.
  • Per Ptc Therapeutics' latest filing, its Non-Current Assets stood at $635.9 million for Q3 2025, which was up 1341.41% from $361.3 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Non-Current Assets high stood at $1.1 billion for Q2 2022, and its period low was $339.0 million during Q1 2025.
  • Its 5-year average for Non-Current Assets is $774.9 million, with a median of $748.4 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 1592.02% in 2021, then plummeted by 4985.84% in 2024.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Non-Current Assets stood at $983.7 million in 2021, then increased by 2.86% to $1.0 billion in 2022, then plummeted by 33.08% to $677.1 million in 2023, then plummeted by 49.86% to $339.5 million in 2024, then surged by 87.31% to $635.9 million in 2025.
  • Its Non-Current Assets stands at $635.9 million for Q3 2025, versus $361.3 million for Q2 2025 and $339.0 million for Q1 2025.